02773: Histotripsy for Treatment of Canine Appendicular Osteosarcoma

One Health: Yes

Abstract

Osteosarcoma (OS) is the most common bone cancer in dogs. Large and giant breeds such as Irish Wolfhound, Great Dane, Greyhound, Scottish Deerhound, Rottweiler, Boxer, Saint Bernard, and Irish Setter are most affected. OS is treated with a combination of surgical removal of the primary tumor and chemotherapy for metastatic disease. Surgical removal of the tumor usually involves limb amputation or limb salvage surgery, which can have high complication rates, and not all dogs are suitable for limb amputation. Even after surgical tumor removal and chemotherapy, the cancer often metastasizes and dogs usually die of metastatic disease within an average of 12 months after diagnosis. Survival times have not greatly improved over the last 30 years. Histotripsy is a precision non-thermal focused ultrasound method that mechanically breaks down tissues, can potentially induce immune activation towards an anti-OS immune response, and is an emerging modality for treating multiple cancers including liver and brain cancer. A non-surgical option for treatment of the primary tumor in OS will help patients preserve their limb and avoid complications of surgical limb-salvage. A therapy that stimulates an anti-tumor immune response may increase OS survival. This study aims to evaluate the efficacy of histotripsy to treat dogs with OS, to ultimately advance the development of histotripsy as a limb salvage treatment option for primary OS and an immunotherapy treatment against metastatic disease for OS.

Publication(s)